- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05532943
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis (UMSC01)
December 4, 2023 updated by: Ever Supreme Bio Technology Co., Ltd.
A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
This study is to identify the safety and efficacy of repeat IV(Intravenous) and IT(Intrathecal) administrations of UMSC01 in patients with MS.
While anti-inflammatory drugs are routinely used for the treatment of MS by inhibiting immune responses, their effects on axon remyelination or neuroregeneration are limited.
The combined systemic delivery of UCMSCs via intravenous injection and local administration of the cells by IT was to have safety and therapeutic efficacy for patients with MS.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
There is single arm in Phase I part: 6 patients will be enrolled sequentially for safety considerations.
The patient will receive UMSC01 via IV followed by IT at day 28 as described in above.
After all patients in Phase I complete the safety assessment by SMC without any major safety issue 4 weeks after the last UMSC01 administration, the Phase IIa part will be initiated.
There are 2 arms in Phase IIa part: Sham-controlled with conventional treatment control and administration of UMSC01 with conventional treatment.
Study Type
Interventional
Enrollment (Estimated)
41
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sammi Hsu
- Phone Number: 886-4-2325-288
- Email: cthsu@ever-supreme.com.tw
Study Contact Backup
- Name: Jack Tsai
- Phone Number: 517 886-4-2325-288
- Email: cktsai@ever-supreme.com.tw
Study Locations
-
-
Non-US
-
Taichung, Non-US, Taiwan, 404
- Recruiting
- China Medical University Hospital
-
Contact:
- Sammi Hsu
- Email: cthsu@ever-supreme.com.tw
-
Principal Investigator:
- Yuh C Guo, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients are willing to sign informed consent.
- Male or female are age between 20 to 65 years old on date of consent.
- Diagnosis of Relapsing-Remitting MS (RRMS) (≥1 clinically documented relapse in the past 12 months, ≥2 clinically documented relapses in the last 24 months or ≥ 1 gadolinium enhanced lesion or T2 new lesion in the last 12 months) or Secondary Progressive MS (SPMS) (EDSS increase ≥1.0 point (baseline EDSS ≤ 5.0) or ≥ 0.5 point (baseline EDSS ≥5.5), and ≥1 clinical relapse or ≥1 gadolinium enhanced lesion in the last 12 months)
- MS diagnosis established between 2 to 15 years and EDSS score between 2.0 to 6.5 before enrollment
- Patient has appropriated blood clotting function as assessed by the following laboratory requirements: PT, APTT ≤ 1.5X upper limit of normal (ULN).
- Treatment failure (either ≥ 1 relapse, ≥ 1 new T2 lesion, ≥ one gadolinium enhanced lesion or EDSS deterioration) with at least one of MS disease modifying therapy as Interferon-β, Glatiramer acetate (Copaxone), Dimethyl fumarate (Tecfidera), Teriflunomide (Aubagio), Fingolimod (Gilenya), Ozanimod (Zeposia), Cladribine (Mavenclad), Siponimod (Mayzent), Ofatumumab (Kesimpta), or Natalizumab (Tysabri) for more than 6 months
- All male patients and female patients with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) for at least 4 weeks after UMSC01 treatment
Exclusion Criteria:
- Pregnancy, lactation, and those who are not pregnant but did not, or unwilling to, take effective contraceptives measures 4 weeks before and after the treatment.
- Patients with uncontrolled diabetes (fasting blood glucose > 250 mg/dL)
- Patients with inadequate hepatic and renal function: AST and ALT > 5X ULN; eGFR < 30 mL/min.
- Patients who are unable to undergo Brain MRI examination for any reason.
- Patients who have medical history or current clinically active malignant tumor, peripheral neuropathy, myopathy or other clinically significant neurological diseases that will confound the evaluation of this study.
- Patients who have immuno-compromised condition or is with known clinically significantly autoimmune conditions other than MS or is receiving immunosuppressive treatments other than MS treatment within 6 months.
- With active infection that required systemic treatment
- Patients who are participating in other clinical trials with an investigational product within 1 month.
- Patients who were treated with cytotoxic medications during the last 1 month prior to the infusion.
- Relapse of MS within1 month before UMSC01 infusion.
- With anti-CD20 therapy, such as rituximab
- Patients not suitable to participate the trial as judged by the Investigator(s)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UMSC01
UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.
|
UMSC01 cells will be IV infusion followed by IT infusion with 12 months of follow up after treatment.
|
Sham Comparator: Placebo
For IV administration, normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.
For IT administration, sham puncture procedure will partially penetrate without reaching subarachnoid space, and no spinal fluid will be drawn.
|
Normal saline will be IV infusion followed by sham-IT infusion with 12 months of follow up after treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Endpoint for Phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
SAE, SUSAR, and AE incidences over the study period
|
from visit 2 to 12-month follow-up period
|
Primary Endpoint for Phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of EDSS to Visit 10
|
from visit 2 to 12-month follow-up period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB for EDSS of follow up visits (Visit 6-10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB for brain MRI parameters of follow-up visits (Visit 6 -10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
Quality of life: CFB for MSQoL-54 questionnaire score of follow-up visits (Visit 6 -10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of T25FW scores of follow-up visits (Visit 6-10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of 9-HPT scores of follow-up visits (Visit 6-10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of PASAT scores of follow-up visits (Visit 6-10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of SDMT scores of follow-up visits (Visit 6-10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of RNFL thickness, measured by OCT of follow-up visits (Visit 6-10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoint for phase I portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of MSFC of follow-up visits (Visit 6-10)
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 6-month follow-up period
|
Time to onset of CDW confirmed by EDSS at least 6 months
|
from visit 2 to 6-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
ARR (Annualized relapse rate), where relapse is defined as new or worsening neurological symptoms lasting for >24 hours
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow-up visits (Visit 6 -10) for EDSS
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow up visits (Visit 6-10) for brain MRI parameters
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
Quality of life: CFB of follow up visits (Visit 6-10) for MSQoL-54 questionnaire score
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow up visits (Visit 6-10) for T25FW scores
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow up visits (Visit 6-10) for 9-HPT scores
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow up visits (Visit 6-10) for PASAT scores
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow up visits (Visit 6-10) for SDMT scores
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow up visits (Visit 6-10) for RNFL thickness, measured by OCT
|
from visit 2 to 12-month follow-up period
|
Efficacy endpoints for phase IIa portion
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of follow up visits (Visit 6-10) for MSFC
|
from visit 2 to 12-month follow-up period
|
The safety endpoints are listed below for both phase I and IIa portions
Time Frame: from visit 2 to 12-month follow-up period
|
SAE, SUSAR, and AE incidences over the study period
|
from visit 2 to 12-month follow-up period
|
The safety endpoints are listed below for both phase I and IIa portions
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of laboratory data to subsequent visits
|
from visit 2 to 12-month follow-up period
|
The safety endpoints are listed below for both phase I and IIa portions
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of physical examination to subsequent visits
|
from visit 2 to 12-month follow-up period
|
The safety endpoints are listed below for both phase I and IIa portions
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of vital signs to subsequent visits
|
from visit 2 to 12-month follow-up period
|
The safety endpoints are listed below for both phase I and IIa portions
Time Frame: from visit 2 to 12-month follow-up period
|
CFB of AFP, CEA, CA199, SCC, IgA, anti-EBV, β-HCG, CA125, CA153, and PSA to Visit 6 (Phase I) or Visit 10 (Phase IIa)
|
from visit 2 to 12-month follow-up period
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The exploratory endpoints are listed below for both phase I and IIa portions
Time Frame: from visit 2 to 12-month follow-up period
|
Immunological markers, including CD3, CD4, CD8 surface markers, IgG, IgM, anti-HLA antibodies and Panel Reactive Antibody Assay in whole blood
|
from visit 2 to 12-month follow-up period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Woei C Shyu, Ever Supreme Bio Technology Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 8, 2023
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Study Registration Dates
First Submitted
September 5, 2022
First Submitted That Met QC Criteria
September 5, 2022
First Posted (Actual)
September 8, 2022
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 4, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ES-CMSC01-D1101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Allogeneic umbilical cord mesenchymal stem cells
-
Ever Supreme Bio Technology Co., Ltd.CompletedAcute Myocardial InfarctionTaiwan
-
PT. Prodia Stem Cell IndonesiaRecruiting
-
Ever Supreme Bio Technology Co., Ltd.Recruiting
-
ENCellCompletedCharcot-Marie-Tooth Disease, Type IAKorea, Republic of
-
Ever Supreme Bio Technology Co., Ltd.Active, not recruiting
-
Acibadem UniversityUnknownDuchenne Muscular DystrophyTurkey
-
Limin RongCompleted
-
Sclnow Biotechnology Co., Ltd.SuspendedOsteonecrosis of Femoral HeadChina
-
Qingdao UniversityUnknownDilated CardiomyopathyChina